Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial.

By N. Galiè, Lewis J. Rubin, M. Hoeper, P. Jansa, H. Al-hiti, G. Meyer, E. Chiossi, Andjela Kusic-Pajic, G. Simonneau. The Lancet, 2008

925 citations recorded by the source corpus.

Subfields: Physiology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/d0ff0755425e14c7442c4990038625f24b75b81f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Physiology

1. T. Satoh

In Pulmonary and Respiratory Medicine

1. G. Simonneau

Citations in the corpus

• Definitions and diagnosis of pulmonary hypertension. (2013, background): “Identifying patients with IPAH earlier in the disease process is likely to be beneficial, allowing targeted therapies to be started before the development of significant right heart failure (46).”
• Pulmonary arterial hypertension (2013, methodology): “echocardiographic and Doppler variables, and time to clinical worsening [107,225-228].”
• Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. (2015, neutral): “Deteriorated 12/252 (5) 16/244 (7) 9/124 (7) 7/120 (6)”